Tracking Is Not One Thing

Submitted by: Richard D. Lippert, Jr.

In breast imaging, tracking is often treated as a single operational function. It is not. This framework identifies and organizes 36 breast imaging tracking modalities — from BI-RADS^® follow-up to survivorship surveillance — into a closed-loop quality infrastructure built to ensure that findings are not only interpreted, but communicated, acted upon, resolved, measured, and learned from.

---

The Research Question

In breast imaging, why is tracking so often treated as one operational task when, in practice, it represents a broad group of quality, safety, communication, navigation, audit, and outcomes systems?

The Central Thesis

In breast imaging, tracking is not a single workflow. It is a layered quality infrastructure that helps ensure breast imaging findings are not only interpreted and reported, but also communicated, acted upon, resolved, measured, and learned from.

This distinction is not semantic. It affects patient safety, diagnostic timeliness, access, equity, patient anxiety, biopsy completion, radiology-pathology concordance, cancer detection, multidisciplinary coordination, and long-term surveillance.

This article organizes 36 breast-imaging and breast-imaging-adjacent tracking methods into a practical framework for breast imaging centers. These methods include BI-RADS^® follow-up, diagnostic resolution, biopsy tracking, patient navigation, EHR triggers, medical outcomes audit, interval cancer review, longitudinal breast density tracking, social-needs tracking, closed-loop referrals, and survivorship surveillance.

The Practical Takeaway: A breast imaging program should not ask only whether it tracks. It should ask what it tracks, why it tracks it, who owns the next step, and whether each tracking process reliably closes the loop.

Why This Matters Now

Breast imaging is one of the most protocol-driven areas of medicine. Screening mammography, diagnostic mammography, breast ultrasound, breast MRI, image-guided biopsy, pathology correlation, risk assessment, and survivorship imaging all depend on timely movement from one step to the next.

Yet tracking failures can occur at any point.

A patient may receive a BI-RADS^® 0 screening result but not complete diagnostic imaging. A BI-RADS^® 3 finding may not receive short-interval follow-up. A BI-RADS^® 4 lesion may not proceed to biopsy promptly. A benign biopsy result may be accepted without adequate imaging-pathology concordance. A result may be documented in the report but not understood by the patient. A referral may be placed but never completed. A patient may miss follow-up because of transportation, insurance, language, work schedule, fear, or fragmented care.

The American College of Radiology describes BI-RADS^® as a system that standardizes breast imaging terminology, report organization, assessment structure, and classification across mammography, ultrasound, and MRI. BI-RADS^® is also closely connected to management recommendations, auditing, outcomes monitoring, peer review, and quality improvement.¹

The FDA's MQSA final rule reinforces that breast imaging quality is not limited to image acquisition and interpretation. It also includes reporting, patient communication, facility oversight, breast density notification, and medical outcomes audit measures such as positive predictive value, cancer detection rate, and recall rate.²

The Practical Takeaway: Based on the available evidence and current quality expectations, breast imaging tracking should be understood as a closed-loop care model, not as a clerical function.

The Problem With Treating Tracking as One Task

When breast imaging programs use the word tracking, different teams may mean very different things.

• A radiologist may think of tracking BI-RADS^® 3 follow-up.
• A lead technologist may think of recall scheduling.
• A navigator may think of barrier resolution.
• An administrator may think of MQSA audit metrics.
• A referring clinician may think of result communication.
• A surgeon may think of biopsy completion and pathology correlation.
• A quality leader may think of disparity dashboards and loss-to-follow-up rates.

All of these are valid. None of them is complete alone.

This is why the single word tracking can create a false sense of security. A practice may be excellent at recall tracking but weak at biopsy tracking. It may track biopsy completion but not radiology-pathology discordance. It may monitor recall rate and cancer detection rate but not whether vulnerable patients experience longer diagnostic delays. It may send results but not confirm that the patient understood and completed the next step.

A mature tracking system must distinguish among process tracking, clinical-resolution tracking, communication tracking, navigation tracking, equity tracking, and outcomes tracking.

A Practical Framework: Five Major Categories

The 36 tracking modalities can be grouped into five major pillars:

• BI-RADS^®-driven sequential follow-up
• Closed-loop diagnostic resolution and biopsy safety
• Communication, navigation, and barrier-resolution tracking
• Outcomes audit, registry benchmarking, and equity measurement
• Longitudinal risk, surveillance, and care-continuum tracking

These categories overlap, but each answers a different quality question:

• BI-RADS^® tracking asks: Was the correct next step completed?
• Diagnostic-resolution tracking asks: Did the abnormality reach a documented endpoint?
• Navigation tracking asks: What prevented follow-up, and was the barrier addressed?
• Audit tracking asks: How well is the program performing over time?
• Equity tracking asks: Is the system working equally well for all patients?
• Longitudinal tracking asks: How does this patient's breast imaging story evolve over years, not just one encounter?

The 36 Tracking Modalities

For each method: what it is, how it is used in practice, the value it adds, and the practical takeaway.

---

01 — Timeliness-of-Follow-Up Tracking After Abnormal Screening

Purpose: Measures how quickly a patient moves from an abnormal screening mammogram to the recommended next step, such as diagnostic mammography, ultrasound, biopsy, or surgical consultation.

In Practice: Often built around time intervals: screening date, abnormal result date, patient notification date, diagnostic appointment date, biopsy date, and final diagnosis date.

Value: Helps identify bottlenecks in scheduling, communication, authorization, transportation, staffing, and referral coordination. In a Breast Cancer Surveillance Consortium study, follow-up after abnormal screening mammography varied substantially among facilities, and follow-up generally took longer when biopsy or surgical consultation was recommended than when additional imaging was recommended.³

A center should not only know its recall rate. It should know how long recalled patients wait for diagnostic completion.

---

02 — Registry-Based Mammography Follow-Up Tracking

Purpose: Uses structured databases or registries to track imaging results, recommendations, follow-up, biopsy, cancer outcomes, and performance metrics.

In Practice: Participation in large-scale mammography registries or internal dashboards modeled after registry logic. The ACR National Mammography Database provides participating practices with semiannual benchmark feedback, including cancer detection rates, positive predictive value rates, and recall rates.⁴

Value: Allows programs to compare local performance with broader benchmarks, helping identify variation that may not be visible when a practice only reviews individual cases.

Registry tracking turns breast imaging quality from anecdote into measurable performance.

---

03 — BI-RADS^®-Stratified Abnormal-Result Tracking

Purpose: Uses BI-RADS^® assessment categories to trigger different follow-up pathways.

In Practice: BI-RADS^® 0, 3, 4, and 5 require different management logic. BI-RADS^® 0 typically requires additional imaging or prior comparison. BI-RADS^® 3 usually requires short-interval follow-up. BI-RADS^® 4 and 5 generally require tissue diagnosis unless clinical circumstances dictate otherwise.¹

Value: Prevents all abnormal results from being treated as equal. It aligns tracking intensity with clinical risk and recommended management.

A tracking system that does not distinguish BI-RADS^® category is likely too blunt for breast imaging quality management.

---

04 — BI-RADS^® 0 Recall and Incomplete-Assessment Tracking

Purpose: Ensures that patients with incomplete screening assessments complete diagnostic imaging or prior-image comparison.

In Practice: A BI-RADS^® 0 should generate a recall pathway that confirms scheduling, completion, final diagnostic assessment, patient communication, and referring-provider communication.

Value: BI-RADS^® 0 is not a diagnosis. It is an incomplete assessment. The NCQA Follow-Up After Abnormal Mammogram Assessment measure specifically addresses timely follow-up after inconclusive BI-RADS^® 0 and high-risk BI-RADS^® 4 to 5 assessments.⁵

A BI-RADS^® 0 result should never disappear into a scheduling queue without ownership.

---

05 — Diagnostic-Resolution Tracking

Purpose: Confirms that an abnormal breast imaging finding reaches a documented endpoint.

In Practice: Resolution may mean benign diagnostic imaging, biopsy-proven benign concordant pathology, biopsy-proven malignancy, surgical consultation, or an appropriate surveillance plan.

Value: One of the most important patient-safety concepts in breast imaging. A result is not truly closed until the clinical question has been resolved or an appropriate follow-up plan has been documented.

Diagnostic-resolution tracking shifts the goal from we issued a report to the patient reached an answer.

---

06 — Time-to-Diagnostic-Resolution Tracking

Purpose: Measures the number of days from abnormal screening or diagnostic finding to a definitive endpoint.

In Practice: Programs may track median days to resolution, percentage resolved within a target timeframe, and variation by modality, site, radiologist, referring practice, insurance type, or patient group.

Value: More informative than appointment completion alone, because it captures the full care sequence. Studies of patient navigation and abnormal screening follow-up frequently use diagnostic resolution and time to diagnostic resolution as meaningful outcomes.⁶

A center may schedule the first diagnostic visit quickly but still have delayed resolution if biopsy access, pathology reporting, or referral handoffs are slow.

---

07 — Patient Navigation Tracking

Purpose: Tracks navigator contacts, barriers, appointment completion, diagnostic workup, biopsy follow-up, and resolution.

In Practice: May include outreach attempts, transportation barriers, language needs, insurance problems, appointment reminders, emotional support, and escalation to care teams.

Value: A 2025 JAMA Internal Medicine meta-analysis of 42 randomized trials found that patient navigation services increased breast and cervical cancer screening and follow-up. For breast cancer screening specifically, navigation was associated with a 50 percent relative increase in screening rates (risk ratio 1.50; 95% CI, 1.30 to 1.75) across 30 trials.⁷

Navigation tracking documents the human work required to make imaging recommendations actionable.

---

08 — Case-Management Tracking After Abnormal Mammography

Purpose: Provides structured follow-up for patients at increased risk of delayed or missed care.

In Practice: Used for patients with complex social needs, multiple abnormal findings, cognitive barriers, language barriers, lack of primary care, or repeated missed appointments.

Value: A systematic review of delayed or failed follow-up after abnormal mammograms concluded that successful breast cancer screening depends on timely follow-up, and that inadequate follow-up undermines the benefits of screening.⁸

Case management helps move high-risk follow-up from passive scheduling to active care coordination.

---

09 — Communication-Mode Tracking

Purpose: Measures how results and next steps are communicated, and whether communication method affects follow-up.

In Practice: May compare phone calls, letters, portal messages, text messages, certified mail, interpreter-supported calls, and direct provider communication.

Value: Communication is not complete just because a message was sent. A PROSPR study examined communication practices and timely follow-up after BI-RADS^® 0 screening assessments, highlighting communication as a measurable contributor to follow-up performance.⁹

Centers should track not only whether results were released, but whether the patient was reached and understood what to do next.

---

10 — Electronic Trigger and EHR-Based Delay Tracking

Purpose: Uses EHR logic to identify delayed follow-up after abnormal mammography.

In Practice: Trigger tools can search for abnormal mammography results without documented follow-up within a defined time window.

Value: Murphy and colleagues evaluated electronic triggers to detect delayed follow-up after mammography; in the VA setting, the tool had a positive predictive value of 71 percent and a negative predictive value of 93 percent for detecting diagnostic and treatment delays.¹⁰

EHR triggers can help find patients who are quietly falling through cracks, but they still require human review and accountability.

---

11 — EHR Reminder and Outreach Tracking

Purpose: Tracks reminders, outreach attempts, overdue abnormal results, and care-team action.

In Practice: EHR reminders can prompt clinicians, navigators, schedulers, or population-health teams when a follow-up action is overdue.

Value: A 2023 cluster randomized clinical trial in JAMA found that a multilevel primary care intervention using EHR reminders and patient outreach, with or without navigation, improved timely follow-up of overdue abnormal cancer screening test results for breast, cervical, colorectal, and lung cancer.¹¹

EHR reminders are useful only when paired with workflow ownership, escalation rules, and documentation.

---

12 — BI-RADS^® 3 Short-Interval Follow-Up Tracking

Purpose: Tracks 6-, 12-, and 24-month surveillance for probably benign findings.

In Practice: Should confirm that patients return for short-interval imaging and that the finding remains stable, resolves, or progresses to biopsy when warranted.

Value: In a National Mammography Database study, BI-RADS^® 3 findings after screening recall had a 1.86 percent cumulative cancer yield through 2 years (810 of 43,628 women), with the majority of cancers diagnosed at or before the 6-month visit. Notably, yield rose with patient age and exceeded 2 percent in women older than 60, so this category is reassuring only when follow-up is reliable and age is considered.¹²

BI-RADS^® 3 is safe only when follow-up is reliable.

---

13 — Biopsy Recommendation and Time-to-Biopsy Tracking

Purpose: Tracks whether a recommended biopsy occurs and how long it takes.

In Practice: Includes tracking from diagnostic assessment to biopsy scheduling, biopsy completion, pathology result, and concordance review.

Value: A 2024 National Mammography Database study evaluated diagnostic evaluation and biopsy after recall from screening mammography using abnormal BI-RADS^® 0 screening mammograms from 2008 through 2021, directly supporting the tracking of both diagnostic evaluation and biopsy timeliness after recall.¹³

Time-to-biopsy is a critical measure of whether a suspicious imaging finding is moving toward diagnosis.

---

14 — Radiology-Pathology Concordance and Discordance Tracking

Purpose: Confirms whether biopsy pathology adequately explains the imaging finding.

In Practice: After image-guided biopsy, the radiologist reviews imaging appearance, biopsy target, sampling adequacy, marker placement, pathology result, and clinical context to determine concordance or discordance.

Value: Concordance assessment is essential because false-negative biopsy results can occur. A review on imaging-pathology concordance after ultrasound-guided breast biopsy emphasizes that radiologists should understand biopsy technique, concordance assessment, and appropriate post-biopsy management.¹⁴

A benign biopsy result is not enough. It must be a benign result that matches the imaging concern.

---

15 — Loss-to-Follow-Up Tracking

Purpose: Identifies patients who do not complete recommended imaging, biopsy, surveillance, or referral.

In Practice: Should include missed appointments, canceled studies not rescheduled, unreachable patients, incomplete referrals, and unresolved abnormal findings.

Value: Loss-to-follow-up is both a patient-safety issue and an equity issue. Patients most likely to miss follow-up may also be those facing the greatest structural barriers.

Every no-show after an abnormal breast imaging result should trigger a defined recovery pathway, not simply a scheduling note.

---

16 — Medical Outcomes Audit Tracking

Purpose: Tracks performance metrics such as true positives, false positives, false negatives, cancer detection rate, recall rate, and positive predictive value.

In Practice: MQSA requires facilities to perform medical outcomes audit activities. The FDA states that the annual medical outcomes audit includes positive predictive value, cancer detection rate, and recall rate for each interpreting physician and for the facility as a whole.²

Value: Helps practices identify performance drift, educational needs, variability, and opportunities for quality improvement.

Outcomes audit is not just a regulatory requirement. It is a learning system.

---

17 — Recall-Rate and Positive Predictive Value Tracking

Purpose: Monitors how often patients are recalled and how often recalls or biopsies identify cancer.

In Practice: Programs may track recall rate, cancer detection rate, PPV1, PPV2, PPV3, biopsy yield, and radiologist-level variation.

Value: Helps balance early detection with the harms of false-positive results, including anxiety, additional imaging, biopsy, cost, and workflow burden. NCI's clinician-facing breast screening summary notes that screening benefits must be considered alongside potential harms such as false positives, false negatives, overdiagnosis, discomfort, radiation risk, psychological harm, and financial stress.¹⁵

Tracking performance is not about lowering recalls at all costs. It is about aligning recalls with diagnostic value.

---

18 — Interval Cancer Tracking and Interval Cancer Audit

Purpose: Reviews cancers diagnosed after a negative screen and before the next scheduled screen.

In Practice: May evaluate prior images, density, tumor biology, screening interval, modality, reader performance, and communication practices.

Value: An international survey of population-based breast screening programs found variability in interval cancer audit practices and noted that many programs conduct programmatic interval cancer audits.¹⁶

Interval cancer review can help a program learn from cancers that emerge between screening episodes, without assuming preventability in every case.

---

19 — Health-Equity and Disparity Tracking in Mammography Follow-Up

Purpose: Stratifies follow-up timeliness and completion by race, ethnicity, language, age, insurance, geography, disability, facility type, socioeconomic vulnerability, and other equity variables.

In Practice: Equity dashboards may compare diagnostic completion rates, time to biopsy, no-show recovery, navigation referrals, and loss-to-follow-up by patient group.

Value: Goldman and colleagues examined timeliness of abnormal mammography follow-up at facilities serving vulnerable women using Breast Cancer Surveillance Consortium-linked Medicare claims, supporting the need to evaluate facility-level follow-up patterns through an equity lens.¹⁷

If a center does not stratify follow-up data, it may not see unequal delays.

---

20 — Longitudinal Breast-Density Tracking

Purpose: Tracks breast density changes across serial mammograms.

In Practice: Can support patient counseling, supplemental screening discussion, risk assessment, and future research into longitudinal risk patterns.

Value: A 2024 BMJ longitudinal study examined trajectories of breast density change over time and subsequent breast cancer risk, suggesting that serial density patterns may provide risk information beyond a single density measurement.¹⁸

Density should not be viewed only as a one-time reporting field. It can be part of a longitudinal risk story.

---

21 — Risk-Trajectory Tracking Using Longitudinal Mammography Data

Purpose: Tracks evolving imaging patterns, breast density, prior findings, biopsies, family history, genetics, and other factors to refine future risk assessment.

In Practice: May integrate imaging history with clinical risk models and high-risk clinic referral pathways.

Value: Promising, but clinical implementation requires validation, transparent algorithms, patient-centered communication, and safeguards against widening inequities.

The future of breast imaging quality will increasingly depend on understanding patient risk over time, not only interpreting today's images.

---

22 — Assessment-Management Concordance Tracking

Purpose: Checks whether BI-RADS^® assessments match appropriate management recommendations.

In Practice: Examples include identifying a BI-RADS^® 4 assessment without a biopsy recommendation, a BI-RADS^® 3 without defined short-interval follow-up, or a suspicious MRI finding with unclear next steps.¹

Value: Protects against reporting inconsistency and reduces ambiguity for referring clinicians, navigators, and patients.

A report is only as useful as the clarity of the management recommendation that follows from the assessment.

---

23 — Closed-Loop Test-Result Tracking

Purpose: Confirms that test results are sent, received, acknowledged, acted upon, and documented.

In Practice: In breast imaging, this applies to imaging results, biopsy pathology, addenda, concordance statements, amended reports, and multidisciplinary recommendations.

Value: A rapid review on closing the loop on test results described the importance of reducing communication failures from evidence, practice, and patient perspectives.¹⁹

Closed-loop result tracking is broader than report delivery. It includes action and documentation.

---

24 — Closed-Loop Referral Tracking

Purpose: Tracks whether referrals are completed and whether the outcome returns to the referring clinician or care team.

In Practice: Breast imaging referrals may include diagnostic imaging, biopsy, breast surgery, medical oncology, radiation oncology, genetics, high-risk clinic, plastic surgery, survivorship care, or community resources.

Value: Patel and colleagues define closing the referral loop as a referral that results in a completed specialist appointment with results available to the primary care physician. This concept is directly relevant to breast imaging handoffs.²⁰

A referral placed is not the same as a referral completed.

---

25 — Care Coordination Tracking

Purpose: Tracks handoffs among radiology, primary care, pathology, surgery, oncology, genetics, navigation, and community support.

In Practice: May include tumor board referral, pathology availability, surgical consultation scheduling, genetics referral, staging imaging, or survivorship transition.

Value: A systematic review of care coordination models and tools emphasizes that coordination is a major health-services function requiring structured models and measurement.²¹

Breast imaging findings often initiate a chain of care. Tracking should make the chain visible.

---

26 — System Navigation and Transition-Support Tracking

Purpose: Tracks patient movement across care settings, especially from screening to diagnosis, biopsy, treatment entry, survivorship, or high-risk surveillance.

In Practice: May include transitions from community screening sites to diagnostic centers, from radiology to surgery, from cancer treatment to surveillance, or from primary care to high-risk programs.

Value: Transition points are high-risk moments for missed communication and delayed care.

The more fragmented the care environment, the more important transition tracking becomes.

---

27 — Primary-Care Panel and Preventive-Care Tracking

Purpose: Identifies patients who are due or overdue for screening mammography within a primary-care population.

In Practice: Primary-care teams may use registries, EHR health-maintenance tools, outreach campaigns, reminders, and population-health dashboards.

Value: The 2024 USPSTF recommendation advises biennial screening mammography for women ages 40 to 74 years (Grade B), making reliable population-level screening identification important for preventive care programs.²²

Screening access begins before the patient arrives at the breast imaging center.

---

28 — Chronic Care Model-Style Registry Tracking

Purpose: Applies chronic-care registry logic to breast screening and follow-up.

In Practice: Includes patient registries, proactive reminders, team-based workflows, decision support, planned follow-up, and population management.

Value: The Chronic Care Model has been widely used to improve ambulatory care and clinical quality systems. While breast screening is not a chronic disease, the registry and proactive-care logic are highly applicable to preventive screening and abnormal-result follow-up.²³

Programs can borrow population-management tools from chronic care to improve follow-up reliability.

---

29 — Community Health Worker Navigation Tracking

Purpose: Tracks community-based outreach, education, screening completion, barrier reduction, and follow-up completion.

In Practice: Community health workers may support patients with language access, cultural trust, transportation, appointment scheduling, and health-system navigation.

Value: The Community Preventive Services Task Force recommends interventions engaging community health workers to increase breast cancer screening, especially in underserved communities.²⁴

Community health workers can extend breast imaging quality beyond the walls of the imaging center.

---

30 — Peer or Lay Navigation Tracking

Purpose: Tracks support provided by trained lay navigators, peer navigators, or community-based support personnel.

In Practice: May include appointment reminders, emotional support, education, language-concordant communication, and practical barrier resolution.

Value: Navigation does not always require a nurse or clinician. For some patients, trusted peer support may improve engagement, reduce fear, and support completion of care.

The value of lay navigation should be measured, not assumed.

---

31 — Social-Needs Navigation Tracking

Purpose: Tracks barriers such as transportation, cost, insurance, language, childcare, food insecurity, housing instability, disability access, fear, and work schedule limitations.

In Practice: Can be embedded in scheduling, navigation intake, EHR forms, or population-health outreach.

Value: The CDC describes patient navigation as helping people obtain health care and other resources needed to be as healthy as possible, and notes that combining strategies can improve cancer screening access and sustainability.²⁵

Social barriers are not outside the imaging workflow if they prevent imaging follow-up.

---

32 — Closed-Loop Community Resource Referral Tracking

Purpose: Tracks whether referrals to transportation, financial assistance, interpretation services, community organizations, or social services actually result in support received.

In Practice: May include electronic community resource referral platforms, navigator documentation, referral status, patient confirmation, and outcome tracking.

Value: A systematic review of electronic community resource referral systems describes these systems as tools that connect patients with supports such as food assistance, utility support, transportation, and housing.²⁶

A community referral is not closed until the patient receives the intended support or an alternative plan is made.

---

33 — mHealth and Mobile Reminder Tracking

Purpose: Tracks text messages, app alerts, portal messages, and mobile-phone interventions used for screening uptake and follow-up adherence.

In Practice: mHealth tools can remind patients of appointments, communicate preparation instructions, prompt scheduling, and support follow-up after abnormal results.

Value: A scoping review of reviews found that mHealth interventions can improve cancer screening uptake and other screening-related outcomes such as knowledge and awareness, although implementation context matters.²⁷

Digital reminders can help, but they must be evaluated for language access, digital literacy, privacy, and equity.

---

34 — Telephone Outreach and Reminder Tracking

Purpose: Tracks phone-based outreach, successful contact, reminder completion, scheduling, and follow-up.

In Practice: Telephone outreach remains especially important for abnormal results, high-risk findings, patients without portal use, patients needing interpreters, and patients who miss appointments.

Value: Under the MQSA final rule, when a final assessment is Suspicious or Highly Suggestive of Malignancy, the facility must provide the patient lay summary within 7 calendar days of the final interpretation, which makes reliable direct contact a safety function, not a courtesy.²⁸

In breast imaging, the phone call is often not old-fashioned. It is essential safety infrastructure.

---

35 — Survivorship Surveillance Tracking

Purpose: Tracks post-treatment imaging surveillance, recurrence monitoring, second primary cancer surveillance, symptoms, aftercare needs, and transitions back to primary care.

In Practice: May include annual mammography after breast-conserving therapy, contralateral breast surveillance, MRI in selected high-risk patients, and communication with oncology and surgery.

Value: Breast cancer follow-up varies from standardized schedules to more personalized surveillance and aftercare models. A 2024 systematic review evaluated evidence on personalized breast cancer follow-up, including cost-effectiveness and outcomes.²⁹

Breast imaging remains central after treatment. Survivorship is part of the imaging continuum.

---

36 — Personalized Surveillance and Risk-Stratified Follow-Up Tracking

Purpose: Tracks individualized imaging follow-up based on recurrence risk, breast density, prior cancer, genetics, family history, treatment history, biopsy history, and patient preference.

In Practice: May include high-risk MRI tracking, supplemental screening, alternating mammography and MRI schedules, post-treatment surveillance, and coordination with genetics or high-risk clinics.

Value: Personalized surveillance is promising, but evidence remains uneven across patient groups, risk models, imaging modalities, and implementation settings. Programs should balance personalization with evidence, access, cost, patient anxiety, and clinical oversight.²⁹

Risk-stratified tracking should improve care without creating inconsistent access or widening disparities.

---

What Breast Imaging Leaders Should Measure

A complete tracking program should include both process metrics and outcome metrics.

Process Metrics

• Time from abnormal screening to diagnostic imaging
• Time from diagnostic recommendation to biopsy
• Percentage of BI-RADS^® 0 exams completed within target timeframe
• Percentage of BI-RADS^® 3 exams completed at 6, 12, and 24 months
• Percentage of biopsy recommendations completed
• Time from biopsy to pathology result
• Percentage of biopsies with documented concordance
• Percentage of abnormal findings reaching diagnostic resolution
• Number of outreach attempts before closure, and loss-to-follow-up rate
• Referral completion rate and navigator barrier categories
• Follow-up stratified by race, ethnicity, language, insurance, geography, age, and facility

Outcome Metrics

• Cancer detection rate, recall rate, and positive predictive value
• False-negative review and interval cancer rate
• Biopsy yield and stage at diagnosis
• Patient experience
• Equity gaps in timeliness and completion
• Multidisciplinary handoff performance

Based on the available evidence, programs should be cautious about measuring only what is easiest to capture. Metrics such as recall rate and cancer detection rate are essential, but they do not fully describe whether the patient completed the recommended pathway or experienced avoidable delay.

Why Tracking Directly Affects Patient Care

1. Tracking reduces diagnostic delay

Abnormal breast imaging is time-sensitive. Not every delay changes outcome, but delays can increase anxiety, prolong uncertainty, complicate scheduling, and delay treatment planning when cancer is present. Timeliness tracking helps a practice distinguish random delay from system delay. If diagnostic imaging is consistently delayed at one site, biopsy access is limited on certain days, or uninsured patients experience longer time-to-resolution, those patterns can be addressed only if they are measured.

2. Tracking improves communication

Patients often remember the emotional impact of an abnormal mammogram more than the wording of the report. Tracking communication mode, successful contact, language access, lay summary delivery, and documented next steps can improve patient understanding. Communication tracking does not guarantee comprehension — it creates a structure for confirming that communication occurred and that the next step was made clear.

3. Tracking supports diagnostic confidence

Radiologists often focus on interpretation quality, but diagnostic confidence also depends on what happens after interpretation. A suspicious lesion that is not biopsied, a benign pathology result that is discordant with imaging, or a BI-RADS^® 3 finding that is never followed weakens the diagnostic process. Concordance tracking and diagnostic-resolution tracking protect the integrity of breast imaging decisions.

4. Tracking improves operational performance

Tracking helps leaders identify where capacity is insufficient. If diagnostic slots are full, biopsy appointments are delayed, pathology addenda are slow, or navigation documentation is inconsistent, the problem becomes visible. Operational excellence is not separate from clinical quality. Timely scheduling, clear communication, biopsy access, and reliable handoffs are quality measures.

5. Tracking advances equity

Equity cannot be improved without measurement. Centers should not assume that all patients experience the same access to follow-up. Stratified tracking can show whether specific groups face longer delays, lower biopsy completion, higher loss-to-follow-up, or less access to supplemental screening and high-risk surveillance. This matters because barriers such as transportation, insurance, language, disability, rural distance, digital access, fear, and lack of paid leave can directly affect follow-up completion.

Implementation: Five Questions Every Tracking System Must Answer

1. What is the trigger?

The trigger may be BI-RADS^® 0, BI-RADS^® 3, BI-RADS^® 4, BI-RADS^® 5, a biopsy recommendation, a discordant pathology result, an overdue screening exam, an interval cancer, or a missed survivorship study.

2. What is the expected next step?

The expected next step must be explicit: diagnostic mammography, targeted ultrasound, MRI, stereotactic biopsy, ultrasound-guided biopsy, MRI-guided biopsy, surgical consultation, genetic counseling, short-interval follow-up, or return to routine screening.

3. Who owns the loop?

Ownership should be clear. Depending on the step, the owner may be radiology, scheduling, the referring clinician, navigation, pathology, surgery, oncology, primary care, or population health.

4. What counts as closure?

Closure should not mean message sent or order placed. Closure should mean that the recommended action occurred, the result was reviewed, the patient and care team were informed, and the next plan was documented.

5. How is failure recovered?

Every tracking system needs escalation rules: repeat calls, certified letters, navigator referral, provider notification, care-team huddle, social-work referral, or administrative review.

Common Failure Points

Breast imaging tracking often fails for predictable reasons:

• The result is sent, but no one confirms the patient understands it.
• The order is placed, but the appointment is never scheduled.
• The appointment is scheduled, but the patient no-shows and is not recovered.
• The biopsy is completed, but concordance is not documented.
• The report recommends follow-up, but the EHR does not trigger a reminder.
• The patient changes health systems, and the loop is lost.
• Radiology assumes primary care owns the loop. Primary care assumes radiology owns it.
• The navigator resolves barriers, but the data are not captured.
• Equity gaps exist, but no one stratifies the metrics.

The Practical Takeaway: Tracking design should be built around predictable failure points, not ideal workflows.

Evidence Limitations and Interpretation

The evidence base for breast imaging tracking is strong in some areas and still developing in others.

Direct breast imaging evidence supports abnormal mammography follow-up, BI-RADS^® 0 recall tracking, BI-RADS^® 3 surveillance, diagnostic-resolution tracking, biopsy tracking, radiology-pathology concordance, patient navigation, medical outcomes audit, interval cancer audit, registry benchmarking, and equity measurement.

Broader evidence from diagnostic safety, primary care, care coordination, social-needs referrals, mHealth, and chronic care models is highly relevant but should be interpreted as breast-imaging-applicable, not always breast-imaging-specific. Closed-loop referral tracking, community resource referral tracking, and chronic-care registry logic are valuable models, but programs should adapt them thoughtfully to breast imaging workflows rather than claiming that all are validated specifically for mammography outcomes.

A Breast Imaging Tracking Maturity Model

Level 1 — Basic Compliance Tracking

The practice tracks required MQSA audit elements, sends result letters, and manages recalls manually. Risk: The practice may meet minimum requirements while still missing follow-up gaps.

Level 2 — BI-RADS^® Follow-Up Tracking

The practice tracks BI-RADS^® 0, 3, 4, and 5 categories with defined next steps. Risk: Follow-up may be tracked as appointment completion rather than diagnostic resolution.

Level 3 — Closed-Loop Diagnostic Tracking

The practice tracks diagnostic resolution, biopsy completion, pathology results, and concordance. Risk: Navigation barriers and equity gaps may remain invisible.

Level 4 — Navigation and Equity Tracking

The practice tracks barriers, outreach, patient navigation, social needs, language access, no-show recovery, and stratified follow-up outcomes. Risk: Data collection may become burdensome unless integrated into workflow.

Level 5 — Longitudinal Learning System

The practice integrates registry benchmarking, interval cancer review, longitudinal density and risk tracking, survivorship surveillance, multidisciplinary handoffs, and continuous quality improvement. Goal: Every meaningful breast imaging finding is followed, communicated, resolved, measured, and learned from.

Practical Recommendations

• Define all trackable events by BI-RADS^® category and clinical pathway.
• Separate recall tracking from diagnostic-resolution tracking.
• Track biopsy recommendation, biopsy completion, pathology result, and concordance as one continuous pathway.
• Use EHR triggers and reminders, but assign human ownership.
• Build navigation documentation around barriers, not just appointment dates.
• Stratify follow-up metrics by equity variables.
• Review interval cancers and false negatives in a learning-focused, nonpunitive framework.
• Monitor recall rate, cancer detection rate, and PPV alongside patient-centered measures.
• Track survivorship imaging as part of the breast imaging continuum.
• Reassess tracking performance regularly through quality meetings, dashboards, and multidisciplinary review.

Conclusion

In breast imaging, tracking is often treated as one operational task. It is not.

Tracking is the connective tissue between image interpretation and patient outcome. It determines whether BI-RADS^® recommendations are completed, whether abnormal results reach resolution, whether biopsies are performed and correlated with pathology, whether patients understand next steps, whether navigation barriers are addressed, whether equity gaps are visible, and whether the practice learns from its outcomes.

A breast imaging center does not need to implement all 36 tracking modalities at the same intensity on day one. But it should understand each one, decide which are essential to its patient population and practice model, assign ownership, and measure whether the loop is truly closed.

The future of high-quality breast imaging will not be defined only by better technology or sharper images. It will be defined by systems that ensure every significant finding is seen, communicated, acted upon, resolved, and used to improve care for the next patient.

References

1. American College of Radiology. BI-RADS^®, Breast Imaging Reporting and Data System. Accessed June 15, 2026.
2. U.S. Food and Drug Administration. Important Information: Final Rule to Amend the Mammography Quality Standards Act (MQSA). Accessed June 15, 2026.
3. Rosenberg RD, Haneuse SJP, Geller BM, et al; Breast Cancer Surveillance Consortium. Timeliness of follow-up after abnormal screening mammogram: variability of facilities. Radiology. 2011;261(2):404–413. doi:10.1148/radiol.11102472.
4. American College of Radiology. National Mammography Database. Accessed June 15, 2026.
5. National Committee for Quality Assurance. Follow-Up After Abnormal Mammogram Assessment (FMA-E). Accessed June 15, 2026.
6. Lee JH, Fulp W, Wells KJ, Meade CD, Calcano E, Roetzheim R. Patient navigation and time to diagnostic resolution: results for a cluster randomized trial evaluating the efficacy of patient navigation among patients with breast cancer screening abnormalities, Tampa, FL. PLoS One. 2013;8(9):e74542. doi:10.1371/journal.pone.0074542.
7. Nelson HD, Cantor AG, Pappas M, Blackie K, Yu Y, Fu R. Patient navigation services for breast and cervical cancer screening and follow-up: a meta-analysis. JAMA Intern Med. 2025;185(8):976–985. doi:10.1001/jamainternmed.2025.1590.
8. Reece JC, Neal EFG, Nguyen P, McIntosh JG, Emery JD. Delayed or failure to follow-up abnormal breast cancer screening mammograms in primary care: a systematic review. BMC Cancer. 2021;21:373. doi:10.1186/s12885-021-08100-3.
9. Schapira MM, Barlow WE, Conant EF, et al. Communication practices of mammography facilities and timely follow-up of a screening mammogram with a BI-RADS^® 0 assessment. Acad Radiol. 2018;25(9):1118–1127. doi:10.1016/j.acra.2017.12.028.
10. Murphy DR, Meyer AND, Vaghani V, et al. Electronic triggers to identify delays in follow-up of mammography: harnessing the power of big data in health care. J Am Coll Radiol. 2018;15(2):287–295.
11. Haas JS, Atlas SJ, Wright A, et al. A multilevel primary care intervention to improve follow-up of overdue abnormal cancer screening test results: a cluster randomized clinical trial. JAMA. 2023;330(14):1348–1358. doi:10.1001/jama.2023.18755.
12. Berg WA, Berg JM, Sickles EA, Burnside ES, Zuley ML, Rosenberg RD, Lee CS. Cancer yield and patterns of follow-up for BI-RADS^® category 3 after screening mammography recall in the National Mammography Database. Radiology. 2020;296(1):32–41. doi:10.1148/radiol.2020192641.
13. Oluyemi ET, Grimm LJ, Goldman L, Burleson J, Simanowith M, Yao K, Rosenberg RD. Rate and timeliness of diagnostic evaluation and biopsy after recall from screening mammography in the National Mammography Database. J Am Coll Radiol. 2024;21(3):427–438. doi:10.1016/j.jacr.2023.09.002.
14. Park VY, Kim EK, Moon HJ, Yoon JH, Kim MJ. Evaluating imaging-pathology concordance and discordance after ultrasound-guided breast biopsy. Ultrasonography. 2018;37(2):107–120. doi:10.14366/usg.17049.
15. National Cancer Institute. Breast Cancer Screening (PDQ), Health Professional Version. Accessed June 15, 2026.
16. Fitzpatrick P, Byrne H, Flanagan F, et al. Interval cancer audit and disclosure in breast screening programmes: an international survey. J Med Screen. 2023;30(1):36–41. doi:10.1177/09691413221122014.
17. Goldman LE, Walker R, Hubbard R, Kerlikowske K; Breast Cancer Surveillance Consortium. Timeliness of abnormal screening and diagnostic mammography follow-up at facilities serving vulnerable women. Med Care. 2013;51(4):307–314. doi:10.1097/MLR.0b013e318280f04c.
18. Park B, Chang Y, Ryu S, Tran TXM. Trajectories of breast density change over time and subsequent breast cancer risk: longitudinal study. BMJ. 2024;387:e079575. doi:10.1136/bmj-2024-079575.
19. Wright B, Lennox A, Graber ML, Bragge P. Closing the loop on test results to reduce communication failures: a rapid review of evidence, practice and patient perspectives. BMC Health Serv Res. 2020;20:897. doi:10.1186/s12913-020-05737-x.
20. Patel MP, Schettini P, O'Leary CP, Bosworth HB, Anderson JB, Shah KP. Closing the referral loop: an analysis of primary care referrals to specialists in a large health system. J Gen Intern Med. 2018;33(5):715–721. doi:10.1007/s11606-018-4392-z.
21. Duan-Porter W, Ullman K, Majeski B, Miake-Lye I, Diem S, Wilt TJ. Care coordination models and tools, systematic review and key informant interviews. J Gen Intern Med. 2022;37(6):1367–1379. doi:10.1007/s11606-021-07158-w.
22. US Preventive Services Task Force. Breast Cancer: Screening. Final Recommendation Statement. Published April 30, 2024. Accessed June 15, 2026.
23. Coleman K, Austin BT, Brach C, Wagner EH. Evidence on the Chronic Care Model in the new millennium. Health Aff (Millwood). 2009;28(1):75–85. doi:10.1377/hlthaff.28.1.75.
24. Community Preventive Services Task Force. Cancer screening: interventions engaging community health workers, breast cancer. Accessed June 15, 2026.
25. Centers for Disease Control and Prevention. Patient navigation. Published May 21, 2024. Accessed June 15, 2026.
26. Drewry MB, Yanguela J, Khanna A, et al. A systematic review of electronic community resource referral systems. Am J Prev Med. 2023;65(6):1142–1152. doi:10.1016/j.amepre.2023.06.001.
27. Schliemann D, Tan MM, Hoe WMK, et al. mHealth interventions to improve cancer screening and early detection: scoping review of reviews. J Med Internet Res. 2022;24(8):e36316. doi:10.2196/36316.
28. U.S. Food and Drug Administration. Mammography Information for Patients; and 21 CFR 900.12(c)(2). Accessed June 15, 2026.
29. van Maaren MC, van Hoeve JC, Korevaar JC, et al. The effectiveness of personalised surveillance and aftercare in breast cancer follow-up: a systematic review. Support Care Cancer. 2024;32(5):232. doi:10.1007/s00520-024-08530-2.

---

ACR BI-RADS® Trademark Notice

BI-RADS® is a registered trademark of the American College of Radiology (ACR). The ACR BI-RADS® Atlas and all related assessment category definitions, benchmark values, and audit methodology guidance are the intellectual property of the American College of Radiology. All references to BI-RADS® in this paper are made solely for informational and educational purposes in the context of clinical communication and patient notification practice. Mammologix is not affiliated with, endorsed by, or sponsored by the American College of Radiology.